Superficial Femoral Artery Stenosis

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

C
CordisFL - Miami Lakes
1 program
S.M.A.R.T.™ Nitinol Stent SystemN/A1 trial
Active Trials
NCT07338890Not Yet Recruiting240Est. May 2026
Abbott
AbbottABBOTT PARK, IL
1 program
femoropopliteal revascularization for TASC C or TASC D lesionN/A1 trial
Active Trials
NCT04434586Recruiting166Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CordisS.M.A.R.T.™ Nitinol Stent System
Abbottfemoropopliteal revascularization for TASC C or TASC D lesion

Clinical Trials (2)

Total enrollment: 406 patients across 2 trials

NCT07338890CordisS.M.A.R.T.™ Nitinol Stent System

Post-Market Clinical Follow-Up of S.M.A.R.T. Family of Stents in Treating Iliac and Femoropopliteal Artery Disease

Start: Jan 2026Est. completion: May 2026240 patients
N/ANot Yet Recruiting
NCT04434586Abbottfemoropopliteal revascularization for TASC C or TASC D lesion

Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions

Start: Jun 2020Est. completion: Jun 2026166 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 406 patients
2 companies competing in this space